BSX
Boston Scientific Corporation
Price Chart
Latest Quote
$45.22
+0.27 (+0.59%)
Current Price
| Previous Close | $44.95 |
| Open | $45.06 |
| Day High | $45.48 |
| Day Low | $44.44 |
| Volume | 13,981,443 |
Stock Information
| Shares Outstanding | 1.49B |
| Total Debt | $11.03B |
| Cash Equivalents | $1.45B |
| Revenue | $20.61B |
| Net Income | $3.56B |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $67.32B |
| P/E Ratio | 18.95 |
| EPS (TTM) | $2.39 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $79.56B |
| Sales | $20.61B |
| Income | $3.56B |
| Book/sh | $17.40 |
| Cash/sh | $0.98 |
| Employees | 59K |
Financial Ratios
| Quick Ratio | 0.98 |
| Current Ratio | 1.90 |
| Debt/Eq | 42.25 |
| EPS Growth TTM | 99.00% |
Returns & Margins
| ROA | 6.07% |
| ROE | 14.66% |
| Gross Margin | 68.94% |
| Operating Margin | 20.60% |
| Profit Margin | 17.29% |
Ownership
| Insider Ownership | 0.23% |
| Institutional Ownership | 94.95% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 12.16 |
| PEG | 0.57 |
| P/S | 3.27 |
| P/B | 2.60 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $77.10 |
Technical Indicators
| SMA20 | $49.26 |
| SMA50 | $54.92 |
| SMA200 | $81.20 |
| RSI | 28.97 |
| ATR | 1.4486 |
| Shares Float | 1.48B |
| Short Float | 3.87% |
| Short Ratio | 2.71 |
| Volatility | 0.56 |
| Rel Volume | 1.33 |
Performance History
| Week | -3.99% |
| Month | -20.28% |
| Quarter | -35.20% |
| 6 Months | -51.27% |
| YTD | -52.18% |
| Year | -55.48% |
| 3 Years | -11.47% |
| 5 Years | +5.55% |
| 10 Years | +98.21% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $45.29 | 30,832,151 |
| 2026-06-17 | $44.95 | 20,824,300 |
| 2026-06-16 | $46.92 | 11,144,100 |
| 2026-06-15 | $46.76 | 16,285,200 |
| 2026-06-12 | $46.91 | 16,762,400 |
| 2026-06-11 | $47.17 | 18,903,200 |
| 2026-06-10 | $48.34 | 22,676,600 |
| 2026-06-09 | $48.96 | 18,210,800 |
| 2026-06-08 | $48.70 | 15,381,600 |
| 2026-06-05 | $48.55 | 20,257,900 |
| 2026-06-04 | $48.85 | 22,783,700 |
| 2026-06-03 | $47.69 | 24,677,000 |
| 2026-06-02 | $47.68 | 21,665,400 |
| 2026-06-01 | $47.98 | 29,188,500 |
| 2026-05-29 | $48.31 | 37,280,100 |
| 2026-05-28 | $49.11 | 44,935,200 |
| 2026-05-27 | $50.46 | 52,740,500 |
| 2026-05-26 | $57.64 | 15,258,000 |
| 2026-05-22 | $57.78 | 11,738,100 |
| 2026-05-21 | $57.15 | 12,841,400 |
| 2026-05-20 | $56.67 | 15,398,800 |
| 2026-05-19 | $56.81 | 22,605,200 |
About Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
đ° Latest News
This Undervalued Medical-Devices Stock Is Poised for a Rebound
Barrons.com âĸ 2026-06-18T11:01:00Z
Penumbra wins CE mark for Thunderbolt clot removal tech
MedTech Dive âĸ 2026-06-18T10:00:00Z
Boston Scientific (BSX) Registers a Bigger Fall Than the Market: Important Facts to Note
Zacks âĸ 2026-06-17T22:00:03Z
Below Expected Outlook Pressured Boston Scientific (BSX) in Q1
Insider Monkey âĸ 2026-06-17T14:12:12Z
Medtech M&A maintains momentum following decade-high 2025: PwC
MedTech Dive âĸ 2026-06-17T11:00:00Z
If Youâre Looking for the âNext Big Thingâ Before the OpenAI and Anthropic IPOs, Try This Barchart Stock Screener
Barchart âĸ 2026-06-15T18:38:40Z
Why Did ADBE, CHWY, BSX Slump To 52-Week Lows Last Week?
Stocktwits âĸ 2026-06-15T02:53:59Z
Truist Reiterates Buy Rating for Boston Scientific (BSX)
Insider Monkey âĸ 2026-06-13T15:29:00Z
Boston Scientific Eyes Neurovascular Growth With Penumbra Thunderbolt Clearance
Simply Wall St. âĸ 2026-06-13T07:17:08Z
Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
Motley Fool âĸ 2026-06-13T04:35:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $5,750,000,000 | $4,844,000,000 | $3,977,000,000 | $3,623,000,000 |
| Cost Of Revenue | $6,221,000,000 | $5,257,000,000 | $4,345,000,000 | $3,956,000,000 |
| Total Revenue | $20,074,000,000 | $16,747,000,000 | $14,240,000,000 | $12,682,000,000 |
| Operating Revenue | $20,074,000,000 | $16,747,000,000 | $14,240,000,000 | $12,682,000,000 |
| Expenses | ||||
| Interest Expense | $349,000,000 | $305,000,000 | $265,000,000 | $470,000,000 |
| Total Expenses | $16,103,000,000 | $13,745,000,000 | $11,823,000,000 | $10,649,000,000 |
| Other Income Expense | $-267,000,000 | $-521,000,000 | $-188,000,000 | $-434,000,000 |
| Other Non Operating Income Expenses | $-35,000,000 | $-29,000,000 | $-14,000,000 | $-16,000,000 |
| Net Non Operating Interest Income Expense | $-320,000,000 | $-198,000,000 | $-243,000,000 | $-460,000,000 |
| Interest Expense Non Operating | $349,000,000 | $305,000,000 | $265,000,000 | $470,000,000 |
| Operating Expense | $9,882,000,000 | $8,488,000,000 | $7,478,000,000 | $6,693,000,000 |
| Other Operating Expenses | $46,000,000 | $33,000,000 | $46,000,000 | $47,000,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $2,898,000,000 | $1,854,000,000 | $1,593,000,000 | $698,000,000 |
| Net Interest Income | $-320,000,000 | $-198,000,000 | $-243,000,000 | $-460,000,000 |
| Interest Income | $29,000,000 | $107,000,000 | $22,000,000 | $10,000,000 |
| Normalized Income | $3,096,128,000 | $2,252,028,000 | $1,732,548,000 | $953,398,000 |
| Net Income From Continuing And Discontinued Operation | $2,898,000,000 | $1,854,000,000 | $1,593,000,000 | $698,000,000 |
| Total Operating Income As Reported | $3,613,000,000 | $2,603,000,000 | $2,343,000,000 | $1,649,000,000 |
| Net Income Common Stockholders | $2,898,000,000 | $1,853,000,000 | $1,570,000,000 | $642,000,000 |
| Net Income | $2,898,000,000 | $1,854,000,000 | $1,593,000,000 | $698,000,000 |
| Net Income Including Noncontrolling Interests | $2,892,000,000 | $1,846,000,000 | $1,592,000,000 | $698,000,000 |
| Net Income Continuous Operations | $2,892,000,000 | $1,846,000,000 | $1,592,000,000 | $698,000,000 |
| Pretax Income | $3,385,000,000 | $2,282,000,000 | $1,985,000,000 | $1,141,000,000 |
| Special Income Charges | $-359,000,000 | $-397,000,000 | $-74,000,000 | $-386,000,000 |
| Interest Income Non Operating | $29,000,000 | $107,000,000 | $22,000,000 | $10,000,000 |
| Operating Income | $3,971,000,000 | $3,002,000,000 | $2,417,000,000 | $2,034,000,000 |
| Depreciation Amortization Depletion Income Statement | $897,000,000 | $856,000,000 | $828,000,000 | $803,000,000 |
| Depreciation And Amortization In Income Statement | $897,000,000 | $856,000,000 | $828,000,000 | $803,000,000 |
| Amortization Of Intangibles Income Statement | $897,000,000 | $856,000,000 | $828,000,000 | $803,000,000 |
| Gross Profit | $13,853,000,000 | $11,490,000,000 | $9,895,000,000 | $8,727,000,000 |
| Per Share | ||||
| Diluted EPS | $1.94 | $1.25 | $1.07 | $0.45 |
| Basic EPS | $1.96 | $1.26 | $1.08 | $0.45 |
| Other | ||||
| Tax Effect Of Unusual Items | $-33,872,000 | $-93,972,000 | $-34,452,000 | $-162,602,000 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $5,334,000,000 | $4,348,000,000 | $3,620,000,000 | $3,165,000,000 |
| Total Unusual Items | $-232,000,000 | $-492,000,000 | $-174,000,000 | $-418,000,000 |
| Total Unusual Items Excluding Goodwill | $-232,000,000 | $-492,000,000 | $-174,000,000 | $-418,000,000 |
| Reconciled Depreciation | $1,368,000,000 | $1,269,000,000 | $1,196,000,000 | $1,136,000,000 |
| EBITDA (Bullshit earnings) | $5,102,000,000 | $3,856,000,000 | $3,446,000,000 | $2,747,000,000 |
| EBIT | $3,734,000,000 | $2,587,000,000 | $2,250,000,000 | $1,611,000,000 |
| Diluted Average Shares | $1,494,500,000 | $1,485,900,000 | $1,463,500,000 | $1,439,700,000 |
| Basic Average Shares | $1,480,400,000 | $1,471,500,000 | $1,453,000,000 | $1,430,500,000 |
| Diluted NI Availto Com Stockholders | $2,898,000,000 | $1,853,000,000 | $1,570,000,000 | $642,000,000 |
| Minority Interests | $6,000,000 | $8,000,000 | $1,000,000 | $0 |
| Tax Provision | $493,000,000 | $436,000,000 | $393,000,000 | $443,000,000 |
| Other Special Charges | $194,000,000 | - | $-111,000,000 | $173,000,000 |
| Impairment Of Capital Assets | $46,000,000 | $386,000,000 | $58,000,000 | $132,000,000 |
| Restructuring And Mergern Acquisition | $119,000,000 | $11,000,000 | $127,000,000 | $59,000,000 |
| Gain On Sale Of Security | $127,000,000 | $-95,000,000 | $-100,000,000 | $-32,000,000 |
| Amortization | $897,000,000 | $856,000,000 | $828,000,000 | $803,000,000 |
| Research And Development | $2,052,000,000 | $1,615,000,000 | $1,414,000,000 | $1,323,000,000 |
| Selling General And Administration | $6,887,000,000 | $5,984,000,000 | $5,190,000,000 | $4,520,000,000 |
| Gain On Sale Of Business | - | $0 | $0 | $-22,000,000 |
| Preferred Stock Dividends | - | - | $23,000,000 | $55,000,000 |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-1,070,000,000 | $-2,003,000,000 | $-1,109,000,000 | $-1,249,000,000 |
| Total Assets | $43,673,000,000 | $39,395,000,000 | $35,136,000,000 | $32,469,000,000 |
| Total Non Current Assets | $34,878,000,000 | $32,477,000,000 | $28,621,000,000 | $26,710,000,000 |
| Other Non Current Assets | $1,866,000,000 | $1,754,000,000 | $572,000,000 | $558,000,000 |
| Non Current Deferred Assets | $3,675,000,000 | $3,655,000,000 | $3,841,000,000 | $3,942,000,000 |
| Non Current Deferred Taxes Assets | $3,675,000,000 | $3,655,000,000 | $3,841,000,000 | $3,942,000,000 |
| Goodwill And Other Intangible Assets | $25,302,000,000 | $23,773,000,000 | $20,390,000,000 | $18,823,000,000 |
| Other Intangible Assets | $7,020,000,000 | $6,684,000,000 | $6,003,000,000 | $5,903,000,000 |
| Current Assets | $8,794,000,000 | $6,920,000,000 | $6,514,000,000 | $5,760,000,000 |
| Other Current Assets | $661,000,000 | $831,000,000 | $333,000,000 | $350,000,000 |
| Prepaid Assets | $299,000,000 | $307,000,000 | $315,000,000 | $264,000,000 |
| Inventory | $2,943,000,000 | $2,810,000,000 | $2,484,000,000 | $1,867,000,000 |
| Receivables | $2,926,000,000 | $2,558,000,000 | $2,228,000,000 | $1,970,000,000 |
| Accounts Receivable | $2,926,000,000 | $2,558,000,000 | $2,228,000,000 | $1,970,000,000 |
| Allowance For Doubtful Accounts Receivable | $-132,000,000 | $-109,000,000 | $-110,000,000 | $-109,000,000 |
| Gross Accounts Receivable | $3,058,000,000 | $2,667,000,000 | $2,338,000,000 | $2,079,000,000 |
| Cash Cash Equivalents And Short Term Investments | $1,965,000,000 | $414,000,000 | $865,000,000 | $928,000,000 |
| Cash And Cash Equivalents | $1,965,000,000 | $414,000,000 | $865,000,000 | $928,000,000 |
| Financial Assets | - | $79,000,000 | $107,000,000 | $149,000,000 |
| Hedging Assets Current | - | $305,000,000 | $159,000,000 | $232,000,000 |
| Restricted Cash | - | $111,000,000 | $130,000,000 | $149,000,000 |
| Assets Held For Sale Current | - | - | - | - |
| Debt | ||||
| Net Debt | $9,346,000,000 | $10,206,000,000 | $8,232,000,000 | $8,002,000,000 |
| Total Debt | $11,436,000,000 | $10,746,000,000 | $9,492,000,000 | $9,282,000,000 |
| Long Term Debt And Capital Lease Obligation | $11,137,000,000 | $8,968,000,000 | $8,961,000,000 | $9,262,000,000 |
| Long Term Debt | $11,012,000,000 | $8,842,000,000 | $8,566,000,000 | $8,910,000,000 |
| Current Debt And Capital Lease Obligation | $299,000,000 | $1,778,000,000 | $531,000,000 | $20,000,000 |
| Current Debt | $299,000,000 | $1,778,000,000 | $531,000,000 | $20,000,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $19,201,000,000 | $17,392,000,000 | $15,606,000,000 | $14,896,000,000 |
| Total Non Current Liabilities Net Minority Interest | $13,762,000,000 | $10,993,000,000 | $10,673,000,000 | $11,093,000,000 |
| Other Non Current Liabilities | $2,405,000,000 | $1,870,000,000 | $625,000,000 | $589,000,000 |
| Non Current Deferred Liabilities | $220,000,000 | $155,000,000 | $445,000,000 | $433,000,000 |
| Non Current Deferred Taxes Liabilities | $220,000,000 | $155,000,000 | $134,000,000 | $144,000,000 |
| Current Liabilities | $5,439,000,000 | $6,399,000,000 | $4,933,000,000 | $3,803,000,000 |
| Other Current Liabilities | $482,000,000 | $582,000,000 | $328,000,000 | $308,000,000 |
| Current Deferred Liabilities | $313,000,000 | $306,000,000 | $266,000,000 | $220,000,000 |
| Payables And Accrued Expenses | $4,345,000,000 | $3,733,000,000 | $3,602,000,000 | $3,024,000,000 |
| Payables | $1,144,000,000 | $960,000,000 | $1,162,000,000 | $1,094,000,000 |
| Accounts Payable | $1,144,000,000 | $960,000,000 | $942,000,000 | $862,000,000 |
| Tradeand Other Payables Non Current | - | $357,000,000 | $470,000,000 | $597,000,000 |
| Total Tax Payable | - | $268,000,000 | $220,000,000 | $232,000,000 |
| Derivative Product Liabilities | - | - | - | $0 |
| Minimum Pension Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $24,232,000,000 | $21,770,000,000 | $19,281,000,000 | $17,574,000,000 |
| Total Equity Gross Minority Interest | $24,472,000,000 | $22,003,000,000 | $19,530,000,000 | $17,573,000,000 |
| Stockholders Equity | $24,232,000,000 | $21,770,000,000 | $19,281,000,000 | $17,574,000,000 |
| Gains Losses Not Affecting Retained Earnings | $-610,000,000 | $275,000,000 | $49,000,000 | $269,000,000 |
| Other Equity Adjustments | $-610,000,000 | $275,000,000 | $49,000,000 | $269,000,000 |
| Retained Earnings | $5,571,000,000 | $2,673,000,000 | $819,000,000 | $-750,000,000 |
| Other | ||||
| Treasury Shares Number | $263,289,848 | $263,289,848 | $263,289,848 | $263,289,848 |
| Preferred Shares Number | $10,062,500 | $10,062,500 | $10,062,500 | $10,062,500 |
| Ordinary Shares Number | $1,483,000,317 | $1,474,556,348 | $1,465,710,376 | $1,433,344,145 |
| Share Issued | $1,746,290,165 | $1,737,846,196 | $1,729,000,224 | $1,696,633,993 |
| Tangible Book Value | $-1,070,000,000 | $-2,003,000,000 | $-1,109,000,000 | $-1,249,000,000 |
| Invested Capital | $35,543,000,000 | $32,390,000,000 | $28,378,000,000 | $26,504,000,000 |
| Working Capital | $3,355,000,000 | $521,000,000 | $1,581,000,000 | $1,957,000,000 |
| Capital Lease Obligations | $125,000,000 | $126,000,000 | $395,000,000 | $352,000,000 |
| Total Capitalization | $35,244,000,000 | $30,612,000,000 | $27,847,000,000 | $26,484,000,000 |
| Minority Interest | $239,000,000 | $233,000,000 | $248,000,000 | $0 |
| Treasury Stock | $2,251,000,000 | $2,251,000,000 | $2,251,000,000 | $2,251,000,000 |
| Additional Paid In Capital | $21,505,000,000 | $21,056,000,000 | $20,647,000,000 | $20,289,000,000 |
| Capital Stock | $17,000,000 | $17,000,000 | $17,000,000 | $17,000,000 |
| Common Stock | $17,000,000 | $17,000,000 | $17,000,000 | $17,000,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $125,000,000 | $126,000,000 | $395,000,000 | $352,000,000 |
| Current Deferred Revenue | $313,000,000 | $306,000,000 | $266,000,000 | $220,000,000 |
| Current Accrued Expenses | $3,201,000,000 | $2,773,000,000 | $2,440,000,000 | $1,930,000,000 |
| Goodwill | $18,282,000,000 | $17,089,000,000 | $14,387,000,000 | $12,920,000,000 |
| Net PPE | $4,035,000,000 | $3,295,000,000 | $3,298,000,000 | $2,831,000,000 |
| Accumulated Depreciation | $-3,610,000,000 | $-3,533,000,000 | $-3,484,000,000 | $-3,282,000,000 |
| Gross PPE | $7,645,000,000 | $6,828,000,000 | $6,782,000,000 | $6,113,000,000 |
| Construction In Progress | $1,161,000,000 | $1,035,000,000 | $857,000,000 | $598,000,000 |
| Machinery Furniture Equipment | $3,827,000,000 | $3,630,000,000 | $3,503,000,000 | $3,297,000,000 |
| Buildings And Improvements | $2,484,000,000 | $2,019,000,000 | $1,843,000,000 | $1,695,000,000 |
| Land And Improvements | $173,000,000 | $144,000,000 | $140,000,000 | $137,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Inventories | $-1,000,000 | - | - | $1,000,000 |
| Finished Goods | $1,849,000,000 | $1,798,000,000 | $1,537,000,000 | $1,171,000,000 |
| Work In Process | $246,000,000 | $193,000,000 | $174,000,000 | $147,000,000 |
| Raw Materials | $849,000,000 | $819,000,000 | $773,000,000 | $548,000,000 |
| Non Current Deferred Revenue | - | $329,000,000 | $311,000,000 | $289,000,000 |
| Long Term Provisions | - | $149,000,000 | $172,000,000 | $212,000,000 |
| Current Provisions | - | $177,000,000 | $206,000,000 | $231,000,000 |
| Investments And Advances | - | $555,000,000 | $413,000,000 | $407,000,000 |
| Other Properties | - | $449,000,000 | $439,000,000 | $386,000,000 |
| Foreign Currency Translation Adjustments | - | - | - | - |
| Non Current Accrued Expenses | - | - | - | - |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $3,404,000,000 | $2,365,000,000 | $1,703,000,000 | $914,000,000 |
| Operating Activities | ||||
| Operating Cash Flow | $4,534,000,000 | $3,435,000,000 | $2,503,000,000 | $1,526,000,000 |
| Cash Flow From Continuing Operating Activities | $4,534,000,000 | $3,434,000,000 | $2,505,000,000 | $1,527,000,000 |
| Operating Gains Losses | $-139,000,000 | $79,000,000 | $59,000,000 | $217,000,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,130,000,000 | $-1,070,000,000 | $-800,000,000 | $-612,000,000 |
| Investing Cash Flow | $-2,640,000,000 | $-5,687,000,000 | $-2,574,000,000 | $-2,011,000,000 |
| Cash Flow From Continuing Investing Activities | $-2,639,000,000 | $-5,687,000,000 | $-2,574,000,000 | $-2,011,000,000 |
| Net Other Investing Changes | $83,000,000 | $23,000,000 | $37,000,000 | - |
| Financing Activities | ||||
| Financing Cash Flow | $-395,000,000 | $1,814,000,000 | $5,000,000 | $-548,000,000 |
| Cash Flow From Continuing Financing Activities | $-395,000,000 | $1,814,000,000 | $6,000,000 | $-547,000,000 |
| Net Other Financing Charges | $-55,000,000 | $-132,000,000 | $-117,000,000 | $-411,000,000 |
| Cash Dividends Paid | - | $0 | $-28,000,000 | $-55,000,000 |
| Preferred Stock Dividend Paid | - | $0 | $-28,000,000 | $-55,000,000 |
| Repurchase Of Capital Stock | - | - | - | $0 |
| Issuance Of Capital Stock | - | - | - | $0 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Net Common Stock Issuance | - | - | - | $0 |
| Common Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-2,049,000,000 | $-529,000,000 | $-4,000,000 | $-3,435,000,000 |
| Issuance Of Debt | $1,558,000,000 | $2,332,000,000 | $0 | $3,270,000,000 |
| Interest Paid Supplemental Data | $319,000,000 | $250,000,000 | $259,000,000 | $450,000,000 |
| Income Tax Paid Supplemental Data | $561,000,000 | $656,000,000 | $512,000,000 | $662,000,000 |
| End Cash Position | $2,147,000,000 | $606,000,000 | $1,055,000,000 | $1,126,000,000 |
| Beginning Cash Position | $606,000,000 | $1,055,000,000 | $1,126,000,000 | $2,168,000,000 |
| Effect Of Exchange Rate Changes | $42,000,000 | $-11,000,000 | $-4,000,000 | $-9,000,000 |
| Changes In Cash | $1,499,000,000 | $-438,000,000 | $-67,000,000 | $-1,033,000,000 |
| Proceeds From Stock Option Exercised | $151,000,000 | $143,000,000 | $126,000,000 | $83,000,000 |
| Net Issuance Payments Of Debt | $-491,000,000 | $1,803,000,000 | $-4,000,000 | $-165,000,000 |
| Net Short Term Debt Issuance | $-1,791,000,000 | $-317,000,000 | $-4,000,000 | $-251,000,000 |
| Short Term Debt Payments | $-1,791,000,000 | $-504,000,000 | $-4,000,000 | $-251,000,000 |
| Net Long Term Debt Issuance | $1,300,000,000 | $2,120,000,000 | $0 | $86,000,000 |
| Long Term Debt Payments | $-258,000,000 | $-25,000,000 | $0 | $-3,184,000,000 |
| Long Term Debt Issuance | $1,558,000,000 | $2,145,000,000 | $0 | $3,270,000,000 |
| Net Business Purchase And Sale | $-1,593,000,000 | $-4,640,000,000 | $-1,811,000,000 | $-1,537,000,000 |
| Purchase Of Business | $-1,593,000,000 | $-4,640,000,000 | $-1,811,000,000 | $-1,542,000,000 |
| Net Intangibles Purchase And Sale | $-254,000,000 | $-280,000,000 | $-89,000,000 | $46,000,000 |
| Purchase Of Intangibles | $-254,000,000 | $-280,000,000 | $-89,000,000 | $-24,000,000 |
| Net PPE Purchase And Sale | $-876,000,000 | $-790,000,000 | $-711,000,000 | $-576,000,000 |
| Purchase Of PPE | $-876,000,000 | $-790,000,000 | $-711,000,000 | $-588,000,000 |
| Change In Working Capital | $-246,000,000 | $-462,000,000 | $-770,000,000 | $-1,005,000,000 |
| Change In Other Current Assets | $-85,000,000 | $-126,000,000 | $10,000,000 | $-209,000,000 |
| Change In Payables And Accrued Expense | $296,000,000 | $243,000,000 | $118,000,000 | $-255,000,000 |
| Change In Payable | $296,000,000 | $243,000,000 | $118,000,000 | $-255,000,000 |
| Change In Account Payable | $296,000,000 | $243,000,000 | $118,000,000 | $-255,000,000 |
| Change In Inventory | $-188,000,000 | $-228,000,000 | $-660,000,000 | $-321,000,000 |
| Change In Receivables | $-269,000,000 | $-351,000,000 | $-238,000,000 | $-220,000,000 |
| Changes In Account Receivables | $-269,000,000 | $-351,000,000 | $-238,000,000 | $-220,000,000 |
| Other Non Cash Items | $192,000,000 | $49,000,000 | $109,000,000 | $191,000,000 |
| Stock Based Compensation | $299,000,000 | $266,000,000 | $233,000,000 | $220,000,000 |
| Asset Impairment Charge | $170,000,000 | $458,000,000 | $85,000,000 | $132,000,000 |
| Deferred Tax | $-2,000,000 | $-70,000,000 | $-1,000,000 | $-63,000,000 |
| Deferred Income Tax | $-2,000,000 | $-70,000,000 | $-1,000,000 | $-63,000,000 |
| Depreciation Amortization Depletion | $1,368,000,000 | $1,269,000,000 | $1,196,000,000 | $1,136,000,000 |
| Depreciation And Amortization | $1,368,000,000 | $1,269,000,000 | $1,196,000,000 | $1,136,000,000 |
| Amortization Cash Flow | $897,000,000 | $856,000,000 | $828,000,000 | $803,000,000 |
| Amortization Of Intangibles | $897,000,000 | $856,000,000 | $828,000,000 | $803,000,000 |
| Depreciation | $471,000,000 | $412,000,000 | $367,000,000 | $333,000,000 |
| Gain Loss On Investment Securities | $-139,000,000 | $79,000,000 | $59,000,000 | $1,000,000 |
| Net Income From Continuing Operations | $2,892,000,000 | $1,846,000,000 | $1,592,000,000 | $698,000,000 |
| Short Term Debt Issuance | - | $187,000,000 | $0 | $0 |
| Net Investment Purchase And Sale | - | $0 | $2,000,000 | $56,000,000 |
| Sale Of Investment | - | $0 | $2,000,000 | $56,000,000 |
| Sale Of Business | - | $0 | $0 | $5,000,000 |
| Sale Of Intangibles | - | $20,000,000 | $30,000,000 | $70,000,000 |
| Sale Of PPE | - | $3,000,000 | $4,000,000 | $12,000,000 |
| Gain Loss On Sale Of Business | - | $0 | $0 | $22,000,000 |
| Common Stock Payments | - | - | - | $0 |
| Purchase Of Investment | - | - | - | $-24,000,000 |
| Net Foreign Currency Exchange Gain Loss | - | - | - | - |
Fetched: 2026-06-18